spec sheet8 rows
Arzoxifene is a benzothiophene selective estrogen receptor modulator (SERM) developed by Eli Lilly and studied for osteoporosis and breast cancer prevention in postmenopausal women. It reduced vertebral fractures and invasive breast cancer risk in Phase 3 trials but was not brought to market.
- Reduced vertebral fracture risk in a large Phase 3 osteoporosis trial
- Reduced invasive breast cancer incidence, particularly ER-positive and PR-positive tumors
- Favorable effect on lipid profile with minimal uterine stimulation, unlike some earlier SERMs
- Increased risk of venous thromboembolic events (blood clots) by roughly 2.3-fold relative to placebo
- As with other SERMs, hot flashes and other estrogen-modulating side effects are expected though not the headline safety finding
Overview
It looked like it might be the 'ideal SERM' on paper, good bone and breast numbers, but the blood clot risk and lack of a clear edge over existing options ended its run.
Mechanism
Arzoxifene binds receptors and produces tissue-selective effects: it acts as an estrogen in breast and endometrial tissue while behaving as an estrogen in bone and on lipid profile. This selective antagonist/agonist pattern is the defining feature of the SERM class and is intended to provide bone-protective and favorable lipid effects without stimulating breast or uterine tissue.
receptor fingerprint
receptor (breast/endometrial tissue)Antagonist
receptor (bone/lipid tissue)Agonist
Safetyrisks and cautions, not medical advice
In a Phase 3 trial in postmenopausal women with osteoporosis, arzoxifene reduced vertebral fracture incidence by about 41% relative risk and reduced invasive breast cancer incidence by about 56% relative risk over the trial period, with little uterine stimulation. However, it also increased the incidence of venous thromboembolic events by roughly 2.3-fold relative risk, an adverse effect shared with other SERMs, which along with a lack of clear superiority over existing options limited its further clinical development.
Subjective profileweighing the evidence above
A drug that worked and still did not make it, with real vertebral fracture and breast cancer reductions offset by roughly a 2.3-fold rise in blood clots. Nothing to seek out; the SERMs that reached market carry the same class trade-off with actual prescribing support behind them.
Resources
This entry is here for reference.
Research
- 1.Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women
- 2.Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene
2 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
What is Arzoxifene used for?
It was studied as a treatment to reduce fracture risk in osteoporosis and to reduce invasive breast cancer risk in postmenopausal women, but it was never approved or marketed.
How does Arzoxifene work?
It's a selective estrogen receptor modulator: it blocks estrogen's effects in breast and uterine tissue while mimicking estrogen's protective effects in bone and on cholesterol levels.
Is Arzoxifene well-researched?
Yes, relative to most compounds on this list; it went through large Phase 3 clinical trials with published efficacy and safety data, but it was ultimately not approved due to blood clot risk and lack of clear advantage over existing therapies.
Adverse effects
- Increased risk of venous thromboembolic events (blood clots) by roughly 2.3-fold relative to placebo
- As with other SERMs, hot flashes and other estrogen-modulating side effects are expected though not the headline safety finding
Notes and cautions
- Never received regulatory approval despite promising efficacy data